What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?
about
The path to routine use of genomic biomarkers in the cancer clinicOverdiagnosis and overtreatment of prostate cancerActive surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypesLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesProstate specific antigen: the past, present and future.Screening for pancreatic cancer: why, how, and who?Prostate-specific antigen testing across the spectrum of prostate cancer.Prostate-cancer mortality at 11 years of follow-up.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Prostate-specific antigen screening in prostate cancer: perspectives on the evidenceWhat do the screening trials really tell us and where do we go from here?Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.Proteomic Profiling of Serum-Derived Exosomes from Ethnically Diverse Prostate Cancer PatientsEconomic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesProphylactic bilateral oophorectomy at time of hysterectomy for women at low risk: acog revises practice guidelines for ovarian cancer screening in low-risk women.PSA mass screening: is there enough evidence?Landmarks in prostate cancer screening.Informed prostate cancer risk-adjusted testing: a new paradigm.Risk stratification in prostate cancer screening.Comparative effectiveness research in localized prostate cancer treatment.Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.Expectant management for men with early stage prostate cancer.Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.Rethinking active surveillance for prostate cancer in African American men
P2860
Q26782733-1DED5014-1904-432B-A536-4FFF76697AD6Q26859596-5E72A3E0-2858-4D8B-AD38-F7D3888F12D8Q27010695-666F412A-8DA6-4F0B-AB13-61755DB0CA14Q28251617-C531002D-F8B9-470E-82FA-2A724D129E3BQ30436923-8C91303D-24EA-462E-A7C2-F846941C01D0Q33959412-51642DAC-5596-494B-B7C3-60A667EF078FQ34210163-EBDB8105-040D-4A28-A430-D547CDA8427EQ34261229-344A4A08-7E48-4B5B-8B5F-A571F58D9625Q34326169-C9810E02-A0EE-40F6-8491-4843E0DE471AQ34354430-1A5E01A0-2535-495E-BFF5-7A1D101284ADQ35234770-78024B77-E3D7-4EAC-876A-6B12E3557319Q35917103-F4EFBFB4-F8FD-4955-94EB-58AC346A48C9Q36145417-99E9EC17-0145-4BAD-A83E-01DB68DADE2BQ36520462-CC604096-D6DE-4A22-8F79-02E4DDD8FE8CQ37095655-FE6AE860-2FD7-4009-8FC9-6BBFB060AF14Q37577656-2B0ABFCC-676F-475A-803E-32D8DBE60E1AQ37579100-B1DA1070-28A3-466E-A102-D652AEACED2DQ38050464-1A8B011F-7FE4-4FEC-9BEE-05298195769EQ38063556-8AFD06D1-0D00-4434-AABC-2A25BBE16A2AQ38068114-C9C10E61-73AA-4534-AEE7-9BA0E48D2AC3Q38162919-24275457-0895-479D-81EB-7C7E81B250AFQ38181600-CDDE5648-B3EA-497F-8634-5D00285A0F14Q38469754-9F47299D-5AA1-48D0-A6DE-2FD7979ADCE3Q39583146-27DCCF34-7CD7-4764-9731-8E8E3375BA12Q40848507-C2C2A041-69C0-4EBC-9AC4-E953B3AA9127Q47812805-6C17146A-0F88-4BDF-8969-C009692513D9Q58562144-55C25ED5-8E22-44A2-883E-61190DF62977
P2860
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
What is the true number needed ...... tate-specific antigen testing?
@ast
What is the true number needed ...... tate-specific antigen testing?
@en
What is the true number needed ...... tate-specific antigen testing?
@nl
type
label
What is the true number needed ...... tate-specific antigen testing?
@ast
What is the true number needed ...... tate-specific antigen testing?
@en
What is the true number needed ...... tate-specific antigen testing?
@nl
prefLabel
What is the true number needed ...... tate-specific antigen testing?
@ast
What is the true number needed ...... tate-specific antigen testing?
@en
What is the true number needed ...... tate-specific antigen testing?
@nl
P2093
P2860
P356
P1476
What is the true number needed ...... tate-specific antigen testing?
@en
P2093
E Jeffrey Metter
Edward F Vonesh
H Ballentine Carter
Peter H Gann
Stacy Loeb
William J Catalona
P2860
P304
P356
10.1200/JCO.2010.30.6373
P407
P577
2010-12-28T00:00:00Z